Halozyme Therapeutics, Inc. (HALO), Friday announced that Johnson & Johnson has received U.S. Food and Drug Administration approval of a new indication for DARZALEX Faspro as a single agent treatment of adult patients with high-risk smoldering multiple myeloma.
The approval is based on the findings from the AQUILA study, which evaluated the efficacy and safety of DARZALEX Faspro.
Co-formulated with the company's drug delivery technology ENHANZE, Halozyme expects the approval to further strengthen DARZALEX Faspro's role as a cornerstone therapy across all stages of multiple myeloma.
Currently, HALO is trading at $68.65, up 0.38 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.